iNK cells
Phase 1Small molecule
iNK cells is one of 83 small molecule programs targeting Leukemia. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
598 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Caitlyn
Bristol-Myers SquibbPhase 3
Beyfortus
BeiGenePhase 3
Camptosar
EEastern Cooperative Oncology Group
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Trodelvy
GileadPhase 3
Etopophos
GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iNK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details